|
| Overview of systematic review of Chinese herbal injections for cor pulmonale |
| Hits 203 Download times 153 Received:January 13, 2024 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2024.05.10 |
| Key Words
Chinese herbal injection;cor pulmonale;methodological quality;reporting quality;grading of evidence;overview of systematic review |
| Author Name | Affiliation | E-mail | | WEI Bin | Beijing University of Chinese Medicine, Beijing 100029, China | | | CHEN Yu | Beijing University of Chinese Medicine, Beijing 100029, China | | | KOU Mengjia | Beijing University of Chinese Medicine, Beijing 100029, China | | | TAN Weili | Beijing University of Chinese Medicine, Beijing 100029, China | | | ZHAO Hantao | Beijing University of Chinese Medicine, Beijing 100029, China | | | JIAO Yang | Dongfang Hospital Beijing University of Chinese Medicine, Beijing 100078, China | yangjiao2013@sina.cn |
|
| Abstract
|
| [Objective] To This study re-evaluated the systematic review/Meta-analysis of traditional Chinese medicine（TCM） injection in the treatment of pulmonary heart disease，in order to provide evidence-based support for clinical application of TCM injection. [Methods] Eight Chinese and English databases，including CNKI，SinoMed，Embase and The Cochrane Library，were searched by computer from March 2023 to collect systematic reviews/meta-analyses of traditional Chinese medicine injection in the treatment of pulmonary heart disease. AMSTAR-2，PRISMA 2020 and GRADE systems were used to evaluate the methodological quality，reporting quality and evidence quality of the included studies. [Results] A total of 26 systematic reviews/Meta-analyses were included，involving 16 TCM injections and 29 outcome indicators. The results of AMSTAR-2 evaluation showed that the methodological quality of the included literatures was generally low，and there were no medium or high quality literatures. Items 2（preliminary scheme），3（reasons for the selection of research types），4（literature search），8（description of research characteristics），and 10（funding sources） had obvious defects. The results of PRISMA2020 showed that the reporting completeness of eight subject items was＜50%：search strategy，method synthesis，credibility evaluation，result synthesis，evidence credibility，registration and proposal，conflict of interest，and supplementary materials. GRADE evaluation results showed that there was no high-quality evidence in the included studies，and low methodological quality，inconsistent results，and publication bias were the main factors for evidence quality degradation. [Conclusion] Based on the existing evidence，it is suggested that Chinese medicine injection is effective and basically safe in the treatment of pulmonary heart disease，which can help to correct the hypoxia state，improve ventricular systolic and diastolic function，reduce pulmonary artery pressure and improve hemorheology indexes in patients with pulmonary heart disease. However，the methodological quality of the published systematic review/Meta-analysis is low，and there are some defects in the literature reports，and the quality of evidence is not high，which affects the reliability of the results. Therefore，more high-quality clinical studies and evidence are needed in the future to provide evidence-based support for the effectiveness and safety of TCM injection in the treatment of pulmonary heart disease. |
|
